期刊
ANNUAL REVIEW OF MEDICINE, VOL 70
卷 70, 期 -, 页码 91-104出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-121217-094234
关键词
respiratory syncytial virus; coronavirus; influenza; nanoparticle display; vaccine development; platform technology; immunization; X-ray crystallography; electron microscopy
资金
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005129, R01AI127521] Funding Source: NIH RePORTER
- NIAID NIH HHS [R01 AI127521] Funding Source: Medline
Enabled by new approaches for rapid identification and selection of human monoclonal antibodies, atomic-level structural information for viral surface proteins, and capacity for precision engineering of protein immunogens and self-assembling nanoparticles, a new era of antigen design and display options has evolved. While HIV-1 vaccine development has been a driving force behind these technologies and concepts, clinical proof-of-concept for structure-based vaccine design may first be achieved for respiratory syncytial virus (RSV), where conformation-dependent access to neutralization-sensitive epitopes on the fusion glycoprotein determines the capacity to induce potent neutralizing activity. Success with RSV has motivated structure-based stabilization of other class I viral fusion proteins for use as immunogens and demonstrated the importance of structural information for developing vaccines against other viral pathogens, particularly difficult targets that have resisted prior vaccine development efforts. Solving viral surface protein structures also supports rapid vaccine antigen design and application of platform manufacturing approaches for emerging pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据